When a serious infection strikes, antibiotics can become some of the most important medicines in a hospital.
Cefepime is one of them.
It is a broad-spectrum antibiotic used against serious bacterial infections, including infections involving difficult Gram-negative organisms such as Pseudomonas aeruginosa. It is also used in situations such as febrile neutropenia, when infection can become particularly dangerous.
But a major new analysis has put this familiar hospital drug back under the microscope.
Published in JAMA Network Open in September 2026, a systematic review and Bayesian meta-analysis examined 110 randomized clinical trials involving 22,608 patients. Overall, the researchers found a 94.4% probability that cefepime was associated with higher odds of death compared with other beta-lactam antibiotics. The estimated odds ratio was 1.10, with a 95% credible interval of 0.98 to 1.24.
That sounds alarming.
But there is a crucial detail: the study does not show that cefepime directly causes death.
And that distinction matters enormously.
A troubling signal—but not a simple verdict
The researchers themselves stopped short of recommending that cefepime be abandoned.
When they looked only at 73 published, peer-reviewed trials involving 15,411 patients, the estimated odds ratio was higher—1.17—with a 98.6% posterior probability that mortality was higher with cefepime. But the inclusion of unpublished and FDA-provided trials weakened the overall estimate. The authors also noted heterogeneity and possible publication bias and called for prospective research into optimized dosing.
In other words, scientists have found a statistical warning light.
They have not established a simple cause-and-effect story.
That is why the accompanying editorial is particularly interesting.
Its title is blunt: “Cefepime and Mortality—A Dosing Problem, Not a Drug Problem.” The authors argue that cefepime remains a useful medication and that the more important question is whether patients receive the right exposure for their individual circumstances.
That interpretation is important—but it should be regarded as an expert perspective, not as something the new study definitively proved.
Why the kidneys matter so much
One reason cefepime has attracted safety concerns is its relationship with kidney function.
Cefepime is eliminated primarily through the kidneys. That means changes in kidney function can substantially affect how much medication remains in the body.
This becomes particularly relevant for older adults.
Kidney function naturally changes with age, and older people are also more likely to experience conditions such as dehydration, acute illness or sudden kidney injury during hospitalization. A person’s kidney function can therefore change during the very illness for which an antibiotic is being given.
That makes antibiotic treatment in an older patient less like following a fixed recipe and more like adjusting to a moving target.
The FDA’s current labeling specifically warns about serious cefepime-associated neurotoxicity, including confusion, altered consciousness, aphasia, myoclonus and seizures. Most reported cases occurred in people with renal impairment who did not receive appropriate dosage adjustment, although neurotoxicity has also occurred despite apparently appropriate adjustment.
When confusion isn’t “just the infection”
This is one of the most important points for families to understand.
Hospitalized older adults can become confused for many reasons. Severe infection itself can affect the brain. Sleep disruption, unfamiliar surroundings, dehydration and other medicines can also contribute to delirium.
But cefepime can be another possible contributor.
The FDA warning means that clinicians need to consider medication-related neurotoxicity when neurological changes appear during treatment—particularly when kidney function is impaired.
That does not mean every confused patient receiving cefepime has antibiotic toxicity.
It means clinicians have another possibility to consider.
And in medicine, recognizing the right possibility can be just as important as recognizing the disease itself.
The older trials tell only part of today’s story
The new analysis stretches across decades of research.
That creates another complication.
Hospital medicine has changed dramatically since many of the trials included in the analysis were conducted. Laboratory testing, kidney-function assessment, antimicrobial stewardship, intensive-care monitoring and approaches to antibiotic administration have all evolved.
The editorial accompanying the study argues that the next step should not simply be another analysis of old data. Instead, it calls for prospective research examining how cefepime should be dosed and monitored in modern clinical practice.
That is an important distinction.
The question is no longer simply, “Is cefepime good or bad?”
It is closer to:
“For which patients, under which circumstances, and with what treatment strategy does cefepime provide the greatest benefit with the least risk?”
That is a much harder question—but also a much more useful one.
Why this matters if you’re over 65
Older adults are often exposed to more medicines, more medical conditions and more changes in organ function than younger patients.
That does not mean cefepime is uniquely dangerous for older people. In fact, the new analysis found the mortality signal among adults generally, not specifically among older adults.
But age can make medication monitoring especially important.
If an older family member is hospitalized with a serious bacterial infection, the medical team will be balancing several competing priorities: treating the infection quickly, choosing an antibiotic likely to work against the suspected organism, accounting for allergies and other medicines, and adjusting treatment as laboratory and culture results become available.
Families do not need to make those decisions themselves.
What matters is understanding that antibiotic treatment in a seriously ill older adult is not always a one-size-fits-all process.
The bigger lesson about powerful medicines
There is something reassuring hidden inside this unsettling story.
Modern medicine increasingly recognizes that the “right drug” is only part of successful treatment.
The patient’s kidney function, infection, other medications, changing physiology and response to treatment can all matter.
Cefepime remains an important hospital antibiotic. The new JAMA Network Open analysis does not establish that it should be discarded. Instead, it adds weight to a longstanding safety debate and suggests that its role deserves careful, modern reassessment.
For patients and families, perhaps the most useful takeaway is simple:
A powerful medicine deserves equally careful monitoring.
And when an older person’s condition changes unexpectedly during a serious infection, clinicians may need to look beyond the infection itself—including at the medicines being used to fight it.
That is not a reason to fear hospital antibiotics.
It is a reason to recognize just how precise modern medicine sometimes needs to be.
Photo by Stephen Andrews: https://www.pexels.com/photo/pvc-in-patient-hand-9765437/